Program
ALN-PNP
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver, led by Regeneron Pharmaceuticals.
Furthest: phase 2, since Dec 5, 20223 company-led studies, 2 open or runningNext primary completion: Aug 10, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 32 open or running | phase 2since Dec 5, 2022 | Dec 5, 2022 | Aug 10, 2027phase 2 · NCT05648214 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 5, 2022First study: phase 2 study in Fatty LiverFirst studyNCT05648214 · 172 planned · United States
- Aug 16, 2023Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT06024408 · 9 enrolled · South Korea
- Apr 7, 2026Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT07527910 · 204 planned · United States
Ahead
- Aug 10, 2027Primary completion: phase 2 study in Fatty LiverNCT05648214
- Mar 15, 2030Primary completion: phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT07527910
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07527910Non-alcoholic Fatty Liver Disease · United States | 2 | Recruiting | Mar 15, 2030 | 204 |
| NCT06024408Non-alcoholic Fatty Liver Disease · South Korea | 1 | Completed | Jul 7, 2025 | 9 |
| NCT05648214Fatty Liver · United States | 2 | Recruiting | Aug 10, 2027 | 172 |
How it is read
Names in the registry
- “ALN-PNP”, 3 entries
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 2 studies
- Fatty Liver, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.